23639243|t|Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
23639243|a|INTRODUCTION: Tenofovir (TDF) with emtricitabine (FTC) and zidovudine (ZDV) is a recognized alternate first-line antiretroviral (ART) regimen for patients who cannot start treatment with non-nucleoside reverse transcriptase inhibitors (NNRTIs). Clinical studies comparing TDF+FTC+ZDV to other regimens are lacking. METHODS: Participants in a trial of early ART in Cote d'Ivoire (Temprano ANRS 12136) started treatment with TDF/FTC plus either efavirenz (EFV) or ZDV (HIV-1+2 dually infected patients and women refusing contraception or previously treated with nevirapine). We compared rates of upper digestive serious adverse events (sAEs) between TDF/FTC+EFV and TDF/FTC+ZDV patients during the first six months of treatment. sAEs were defined as either grade 3-4 AEs or persistent grade 1-2 AEs leading to drug discontinuation. RESULTS: A total of 197 patients (76% women, median CD4 count 395/mm(3)) started therapy with TDF/FTC, 126 with EFV and 71 with ZDV. During the first six months of ART, 94 patients had digestive AEs (nausea/vomiting) of any grade (EFV 36/126, 29%; ZDV 58/71, 82%, p<0.0001), including 20 sAEs (EFV 3/126, 5%; ZDV 17/71, 24%, p<0.0001). In-patients on TDF/FTC+ZDV with digestive AEs, the median time to the first symptom was two days (IQR: 1-4). Plasma ZDV (Cmax) distributions and pill ZDV dosages were normal. Patients with digestive AEs had higher haemoglobin levels and tended to have higher body mass indices and more frequent past histories of cotrimoxazole (CTX) prophylaxis. CONCLUSIONS: We observed an unexpectedly high rate of digestive sAEs in West African adults, mostly women, who started a 3-nuc ART with TDF/FTC+ZDV in Cote d'Ivoire. These adults were participating in a trial of early ART and had much higher CD4 counts than those who currently routinely start ART in sub-Saharan Africa. They all received CTX concomitantly with ZDV. We suggest that further early prescriptions of TDF+XTC+ZDV should be carefully monitored and that whenever possible, the rate of early upper digestive adverse events should be compared to that occurring in-patients taking other drug regimens. CLINICAL TRIAL NUMBER: NCT00495651.
23639243	44	54	zidovudine	Chemical	MESH:D015215
23639243	60	69	tenofovir	Chemical	MESH:D000068698
23639243	75	88	emtricitabine	Chemical	-
23639243	122	125	CD4	Gene	920
23639243	148	157	Tenofovir	Chemical	MESH:D000068698
23639243	159	162	TDF	Chemical	MESH:D000068698
23639243	169	182	emtricitabine	Chemical	-
23639243	193	203	zidovudine	Chemical	MESH:D015215
23639243	205	208	ZDV	Chemical	MESH:D015215
23639243	280	288	patients	Species	9606
23639243	321	368	non-nucleoside reverse transcriptase inhibitors	Chemical	-
23639243	370	376	NNRTIs	Chemical	-
23639243	406	413	TDF+FTC	Chemical	-
23639243	414	417	ZDV	Chemical	MESH:D015215
23639243	557	564	TDF/FTC	Chemical	-
23639243	577	586	efavirenz	Chemical	MESH:C098320
23639243	588	591	EFV	Chemical	MESH:C098320
23639243	596	599	ZDV	Chemical	MESH:D015215
23639243	601	608	HIV-1+2	Disease	MESH:D015658
23639243	616	624	infected	Disease	MESH:D007239
23639243	625	633	patients	Species	9606
23639243	638	643	women	Species	9606
23639243	694	704	nevirapine	Chemical	MESH:D019829
23639243	782	793	TDF/FTC+EFV	Chemical	-
23639243	798	805	TDF/FTC	Chemical	-
23639243	806	809	ZDV	Chemical	MESH:D015215
23639243	810	818	patients	Species	9606
23639243	988	996	patients	Species	9606
23639243	1002	1007	women	Species	9606
23639243	1016	1019	CD4	Gene	920
23639243	1058	1065	TDF/FTC	Chemical	-
23639243	1076	1079	EFV	Chemical	MESH:C098320
23639243	1092	1095	ZDV	Chemical	MESH:D015215
23639243	1136	1144	patients	Species	9606
23639243	1149	1162	digestive AEs	Disease	MESH:D004828
23639243	1164	1171	nausea/	Disease	MESH:D009325
23639243	1171	1179	vomiting	Disease	MESH:D014839
23639243	1195	1198	EFV	Chemical	MESH:C098320
23639243	1212	1215	ZDV	Chemical	MESH:D015215
23639243	1258	1261	EFV	Chemical	MESH:C098320
23639243	1273	1276	ZDV	Chemical	MESH:D015215
23639243	1303	1311	patients	Species	9606
23639243	1315	1322	TDF/FTC	Chemical	-
23639243	1323	1326	ZDV	Chemical	MESH:D015215
23639243	1332	1345	digestive AEs	Disease	MESH:D004828
23639243	1416	1419	ZDV	Chemical	MESH:D015215
23639243	1450	1453	ZDV	Chemical	MESH:D015215
23639243	1475	1483	Patients	Species	9606
23639243	1489	1502	digestive AEs	Disease	MESH:D004828
23639243	1613	1626	cotrimoxazole	Chemical	MESH:D015662
23639243	1746	1751	women	Species	9606
23639243	1782	1789	TDF/FTC	Chemical	-
23639243	1790	1793	ZDV	Chemical	MESH:D015215
23639243	1888	1891	CD4	Gene	920
23639243	2008	2011	ZDV	Chemical	MESH:D015215
23639243	2060	2063	TDF	Chemical	MESH:D000068698
23639243	2064	2067	XTC	Chemical	MESH:D018817
23639243	2068	2071	ZDV	Chemical	MESH:D015215
23639243	2219	2227	patients	Species	9606
23639243	Negative_Correlation	MESH:D015215	MESH:D007239
23639243	Negative_Correlation	MESH:C098320	MESH:D007239
23639243	Positive_Correlation	MESH:C098320	MESH:D009325
23639243	Negative_Correlation	MESH:C098320	MESH:D015658
23639243	Comparison	MESH:C098320	MESH:D015215
23639243	Negative_Correlation	MESH:D019829	MESH:D015658
23639243	Positive_Correlation	MESH:C098320	MESH:D004828
23639243	Cotreatment	MESH:D015215	MESH:D015662
23639243	Cotreatment	MESH:C098320	MESH:D000068698
23639243	Negative_Correlation	MESH:D015215	MESH:D015658
23639243	Positive_Correlation	MESH:D015215	MESH:D014839
23639243	Positive_Correlation	MESH:C098320	MESH:D014839
23639243	Cotreatment	MESH:D000068698	MESH:D015215
23639243	Positive_Correlation	MESH:D015215	MESH:D004828
23639243	Association	MESH:D015662	MESH:D004828
23639243	Positive_Correlation	MESH:D015215	MESH:D009325

